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Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) results in coronavirus disease 2019 (COVID-19),
which was declared an official pandemic by the World Health
Organization on March 11, 2020. The infection has been reported
in most countries around the world. As of August 2020, there have
been over 21 million cases of COVID-19 reported worldwide, with
over 800 000 COVID-19–associated deaths. It has become apparent that although COVID-19 predominantly affects the respiratory
system, many other organ systems can also be involved. Imaging
plays an essential role in the diagnosis of all manifestations of the
disease, as well as its related complications, and proper utilization
and interpretation of imaging examinations is crucial. With the
growing global COVID-19 outbreak, a comprehensive understanding of the diagnostic imaging hallmarks, imaging features, multisystemic involvement, and evolution of imaging findings is essential
for effective patient management and treatment. To date, only a
few articles have been published that comprehensively describe the
multisystemic imaging manifestations of COVID-19. The authors
provide an inclusive system-by-system image-based review of this
life-threatening and rapidly spreading infection. In part 1 of this
article, the authors discuss general aspects of the disease, with an
emphasis on virology, the pathophysiology of the virus, and clinical
presentation of the disease. The key imaging features of the varied
pathologic manifestations of this infection that involve the pulmonary and peripheral and central vascular systems are also described.
Part 2 will focus on key imaging features of COVID-19 that involve
the cardiac, neurologic, abdominal, dermatologic and ocular, and
musculoskeletal systems, as well as pediatric and pregnancy-related
manifestations of the virus. Vascular complications pertinent to each
system will be also be discussed in part 2.
Online supplemental material is available for this article.
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SA-CME LEARNING OBJECTIVES
After completing this journal-based SA-CME activity, participants will be able to:
 Describe the pathophysiology and clinical presentation of SARS-CoV-2, as well as
its effects on the immune system and coagulatory pathway.
 Discuss the most appropriate imaging modalities and current radiologic recommen-

dations for the diagnosis of pulmonary and vascular manifestations of COVID-19 and
their related complications.
 Recognize key imaging features of the pulmonary and peripheral and central vascu-

lar manifestations of COVID-19, as well as their complications.
See rsna.org/learning-center-rg.

RG • Volume 40 Number 6

TEACHING POINTS
 Respiratory illness is the most commonly associated manifes-

tation of SARS-CoV-2. This is due to abundant ACE2 receptor
expression in the lung parenchyma, specifically on the acinar
side of lung epithelial cells (pneumocytes) within the alveolar
spaces, allowing virus entry. This correlates with the observation that the earliest lung injury is often seen in the distal
airways.
 Chest radiography and chest CT may be performed as ad-

juncts in cases of an initial negative RT-PCR test with persistent
high clinical suspicion for disease.

Revzin et al

describe in detail the key imaging features of the
varied pathologic manifestations of this infection
that involve the pulmonary and peripheral and
central vascular systems.
All medical professionals, including radiologists,
have been given the daunting task of recognizing the varied presentations and complications of
COVID-19 to ensure prompt diagnosis and thereby
limit viral spread, as well as provide appropriate
care to patients with the goal of improving recovery.

 Similar to those at chest radiography, the most suspicious CT

features for COVID-19 infection in the lungs include multifocal
bilateral peripheral GGOs, with or without focal consolidations,
in lung regions close to pleural surfaces, including the fissures.
 Patients admitted to the ICU with barotrauma as a result of

intubation or as a complication of ARDS may develop pneumothoraces or pneumomediastinum, further complicating
the pulmonary manifestations of COVID-19 infection.
 There is growing evidence of coagulopathy related to

COVID-19, which may predispose patients to both venous
and arterial thromboembolism and result in DVT, PE, limb ischemia, stroke, and myocardial infarction. Although the pathogenesis and incidence of thrombotic complications are not
clearly understood, coagulopathy has been noted to be a poor
prognostic indicator and is associated with higher mortality.

Introduction

In December 2019, a novel coronavirus, severe
acute respiratory syndrome coronavirus 2 (SARSCoV-2), was identified as the cause of a cluster of
pneumonia cases in Wuhan, a city in the Hubei
province of China. In the first few months of
2020, infection with this novel coronavirus led to
a global pandemic that has now affected almost
every country in the world, and, by August 2020,
over 21 million cases had been documented (1,2).
Although SARS-CoV-2 disease (or coronavirus
disease 2019 [COVID-19]) primarily manifests
as a lung infection, with symptoms ranging from
those of a mild upper respiratory infection to
severe pneumonia and acute respiratory distress
syndrome (ARDS), other multisystemic manifestations of this disease and related complications
are becoming more commonly recognized (3).
In this article, we provide an inclusive review of
this potentially life-threatening and highly contagious infection, with emphasis on clinical presentation, the pathophysiology of the virus, and the role
of imaging in diagnosing and monitoring the viral
infection and its related complications. We provide
a system-by-system review of the key imaging
features of the various pathologic manifestations
known to date, as well as offer relevant prognostic information that can be inferred from imaging findings. In part 1 of this article, we discuss
general aspects of the disease, with an emphasis
on virology, the pathophysiology of the virus, and
clinical presentation of the disease. In addition, we
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Background
Virology
Coronaviruses are nonsegmented enveloped RNA
viruses with a single-strand linear positive-sense
RNA (4,5). Six types of coronavirus have been
identified that cause human disease. Four of
these cause mild respiratory symptoms whereas
the other two, Middle East respiratory syndrome
(MERS-CoV) coronavirus and severe acute respiratory syndrome coronavirus (SARS-CoV-1), have
previously resulted in epidemics with high mortality rates (6). Although the genome of SARSCoV-2 is 80% identical to that of SARS-CoV-1,
it is more similar to the genome of bat coronaviruses (96% identical) (7). Both SARS-CoV-1 and
SARS-CoV-2 have similar receptor-binding gene
regions, thus for cell entry both viruses use the
same angiotensin-converting enzyme 2 (ACE2)
receptor (7). Currently, two different types of
SARS-CoV-2 have been identified. However, the
implications of this finding are uncertain (8).

Diagnosis
COVID-19 is generally diagnosed with the results
of a real-time reverse transcription–polymerase
chain reaction (RT-PCR) test of a nasopharyngeal
specimen obtained with a swab. However, this
test may obtain false-negative results owing to a
variety of factors, including insufficient viral load,
improper collection of viral samples, and technical
errors during the swabbing procedure (9,10).

Epidemiology
More than 21 million confirmed cases of COVID-19 have been reported to date around the
world, within all continents except for Antarctica,
and the incidence has been steadily rising (11). In
the United States, COVID-19 has been reported
in all 50 states, the District of Columbia, and at
least four territories (12). The cumulative incidence varies by state and is likely dependent on a
number of factors, including population density
and demographics, the extent of testing and reporting, and the initiation of mitigation strategies.
In the United States, outbreaks in long-term care
facilities and homeless shelters have underscored
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the risk of exposure and infection in group settings
(13). The main mode of transmission is person to
person. However, other sources of transmission
have also been implicated (14–16). Person-toperson transmission is thought to occur mainly
through respiratory droplets that are released in a
cough or sneeze or during conversation. Droplets
typically do not travel more than 6 ft (about 2 m)
and are not thought to linger in the air, although
this notion has been challenged (14–16).
Environmental contamination also plays a
role in viral transmission and occurs through
droplet accumulation on frequently touched
surfaces, with subsequent spread to susceptible
mucous membranes within the mouth, nose, and
eyes (14–16). Men are disproportionately more
commonly affected by an infection with SARSCoV-2, and the in-hospital mortality rate among
male patients is significantly higher compared
with that of female patients (17).

Viral Shedding and Infectivity
There is uncertainty regarding the time interval during which an individual with COVID-19
is infectious. It appears that the virus can be
transmitted before the development of symptoms
and throughout the course of illness. However,
definitive data are not yet available, as most information on this subject comes from studies that
evaluated the presence of viral RNA in respiratory and other specimens, which may not correlate with infectivity.
Transmission of SARS-CoV-2 from asymptomatic individuals (or individuals within the
incubation period) has been well documented
(18–22). However, the extent to which asymptomatic and presymptomatic transmission occurs
and their relative contribution to the spread of
the pandemic remain unknown. The length of
time an individual remains infectious is also uncertain. The duration of viral shedding is variable,
and there appears to be a wide range, which may
be dependent on the severity of illness (23–25).

Mechanism of SARS-CoV-2
Invasion into Host Cells

The life cycle of the virus within the host consists of
the following five steps: (a) attachment, (b) penetration (viral entry to the cell), (c) biosynthesis
(viral replication), (d) maturation (assembly and accumulation), and (e) release (through cell destruction). ACE2 has been identified as a functional
receptor for SARS-CoV-2 (26). In the human body,
ACE2 expression is high in the lung (expressed on
lung epithelial cells), heart, gastrointestinal system,
kidney, pancreas, spleen, bladder, cornea, and
blood vessels (27,28). SARS-CoV-2 enters a human
cell by binding its spike or S protein to the ACE2
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receptor of the host, with subsequent fusion of the
viral and cell membranes (endocytosis), resulting in
viral cell entry and depletion of ACE2 receptors on
the cell surface (29). Once within a cell, the virus
activates the intracellular immune system, which
causes immune and nonimmune cells to release
large amounts of proinflammatory cytokines that
activate a cytokine storm and result in damage to
the host (30) (Fig 1).

Immunity
Antibodies to the virus are induced in those
patients with SARS-CoV-2 infection. However,
it is unknown whether all patients with SARSCoV-2 infection mount a protective immune
response and how long any protective effect will
last. Preliminary data on protective immunity are
beginning to emerge (31,32).

Clinical Features

The incubation period for COVID-19 is believed
to be less than 14 days following exposure, with
most cases manifesting 4–5 days after exposure
(19,33–35). The clinical presentation spectrum
varies and includes mild to moderate symptoms
(80%), severe symptoms (14%–15%), and critical
illness (5%). There is increasing evidence that
many patients with COVID-19 are asymptomatic
yet are able to transmit the virus to others. On
the basis of data from several most recent metaanalyses, it has been estimated that approximately
15%–45% of patients with confirmed COVID-19
are asymptomatic. However, it is important to
recognize that a large percentage of patients with
no symptoms at the time of detection will become
symptomatic later. For a more accurate estimation
of patients with confirmed COVID-19 who remain asymptomatic throughout the disease course,
longitudinal data must be collected over a sufficient period of time to allow distinction between
asymptomatic and presymptomatic cases (36,37).
In addition, various studies have reported that
children are likely to have a higher proportion of
asymptomatic infection than adults. However,
the largest meta-analysis and systematic review
studies to date report that only approximately
17%–27.7% of confirmed pediatric cases are asymptomatic (37,38). As with the adult population,
the accuracy of this reported data remains unclear,
as there are significant concerns regarding potential selection bias and testing error.
The most common symptoms at presentation
are fever, cough, and shortness of breath. Mild
to moderate disease is generally characterized by
constitutional symptoms and the possible development of mild pneumonia, while symptoms
of severe disease include dyspnea and hypoxia,
as well as more than 50% lung involvement at
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Figure 1. Illustration shows the proposed mechanism of SARS-CoV-2 cell entry and activation of the immune
system. SARS-CoV-2 enters human cells by attaching to a cell surface receptor (ACE2) and by utilizing a human
enzyme called transmembrane serine protease 2 (TMPRSS2). Once bound to the receptor, SARS-CoV-2 undergoes
endocytosis and enters into the cell, along with the ACE2 receptor. This process reduces the number of ACE2
receptors on cells, leading to an increase of angiotensin II (AngII) levels in the blood. Angiotensin II triggers an
inflammatory pathway involving NF-κB and interleukin 6–signal transducer and activator of transcription 3 protein
(IL-6-STAT3), particularly in nonimmune cells including endothelial and epithelial cells. This pathway forms a positive feedback cycle, named IL-6 amplifier (IL-6 AMP), resulting in its excessive activation and therefore the cytokine
storm and ARDS. Part of this pathway involving NF-κB, IL-6-STAT3, or both is enhanced with age, which could
be the reason why older patients are more at risk for death following COVID-19 diagnosis compared with other
age groups. S1 = viral spike protein subunit 1, S2 = viral spike protein subunit 2,TNF-a = tumor necrosis factor-α.

imaging within 24–48 hours of symptom onset.
Critically ill patients are diagnosed with respiratory failure, shock, or multiorgan dysfunction
(39–44). Although most symptoms are respiratory in nature, clinical features of the disease may
vary, with both typical and atypical presentations
(Table 1). Recovery time appears to be around
2 weeks for mild infections and 3–6 weeks for
severe disease (46).

Complications
The SARS-CoV-2 virus has the potential to cause
complications in every body system. ARDS is a
major complication of severe COVID-19, seen in
20%–40% of patients with severe symptoms, and
typically develops within 6–8 days after the onset
of dyspnea. Up to 12% of patients with ARDS
will require mechanical ventilation (47,48).
ARDS is usually seen in patients greater than 65
years of age and/or those with risk factors (discussed in the following section) (48).
Cardiac complications include arrhythmias
(including atrial fibrillation), acute myocarditis,
cardiomyopathy, and shock (47,49). Abdominal
and/or pelvic solid organ injury is also commonly
seen. Thromboembolic complications, including
pulmonary embolism (PE), peripheral venous
and arterial thrombosis, and acute stroke (seen
also in patients older than 50 years without risk
factors) have all been reported (50–57).

Impact of Age and Underlying Conditions
Individuals of any age can acquire SARS-CoV-2
infection, although adults middle-aged and older
are most commonly affected, and older adults
are more likely to experience severe disease
(41,42,58). Older age is also associated with increased mortality (41,42,58). Eighty-seven percent
of patients diagnosed with COVID-19 are 30–79
years of age (41), and 80% percent of reported
deaths have occurred in those aged greater than
or equal to 65 years. Children are significantly less
affected and exhibit a milder spectrum of disease.
An increased risk of developing severe illness
and increased mortality have been reported in
patients with underlying cardiovascular disease,
diabetes mellitus, hypertension, chronic lung disease, cancer (particularly hematologic malignancies, lung cancer, and metastatic disease), obesity,
and chronic kidney disease (44,59–61). The
Centers for Disease Control and Prevention also
includes immunocompromised status and liver
disease as potential risk factors for severe illness,
although specific data regarding risks associated
with these conditions are limited.

Laboratory Test Findings

Common laboratory test findings in those patients
admitted to the hospital with COVID-19 include
lymphopenia and elevated aminotransaminase,
lactate dehydrogenase, and inflammatory marker
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Table 1: Typical and Atypical Clinical Features of COVID-19
Typical Features

Occurrence (%)

Atypical Features

Occurrence (%)

88
70
68
40
35
31
27
19–34
10
9
4

Neurologic
Muscle pain
Skin rash
Sore throat
Psychiatric
Headache
Rhinorrhea
Chest pain
Pseudochilblain
Conjunctivitis
Guillain-Barré syndrome

50
29
20
17
14
12
<7
5–50
<5
<3
NA*

Fever
Fatigue
Dry cough
Anorexia
Myalgia
Dyspnea
Sputum production
Anosmia and dysgeusia
Diarrhea
Abdominal pain
Nausea and vomiting
Source.—Reference 45.
*NA = not available.

Table 2: Laboratory Test Results Associated with Worse Outcomes in COVID-19
Findings
Lymphopenia
Elevated liver enzymes
Elevated LDH levels
Elevated inflammatory markers (eg, CRP, ferritin)
Elevated d-dimer levels (>0.5 mcg/mL)
Elevated prothrombin time
Elevated troponin levels
Elevated CPK levels

Normal Values
20%–40%
ALT, 6–34 U/L; AST, 11–33 U/L
120–141 U/L
CRP, 10 mg/L; ferritin, 20–250 ng/mL (men), 10–120 ng/mL
(women)
d-dimer <231 DDU ng/mL
10.5–13.3 sec
<0.03 ng/mL
10–120 mcg/L

Source.—Reference 23.
Note.—ALT = aminotransferase, AST = aspartate aminotransferase, CPK = creatinine phosphokinase, CRP =
C-reactive protein, LDH = lactate dehydrogenase.

levels (eg, ferritin, C-reactive protein, and erythrocyte sedimentation rate) (34,62,63). Lymphopenia
is particularly common and is characterized by
a lymphocyte count less than 1500/microL. Up
to 13% of patients have leukocytosis (>10 000/
microL) and 15% of patients have leukopenia
(<4000/microL) (63). In those patients who
require treatment in the intensive care unit (ICU)
for pneumonia and/or other multisystem manifestations, serum procalcitonin levels are more likely
to be elevated (41,62). Several laboratory test features, including elevated d-dimer levels (>2.0 mg/
mL) and severe lymphopenia, have been associated with higher mortality rates (Table 2) (41,45).

Pulmonary Manifestations
of COVID-19

Respiratory illness is the most commonly associated
manifestation of SARS-CoV-2. This is due to abundant ACE2 receptor expression in the lung paren-

chyma, specifically on the acinar side of lung epithelial cells (pneumocytes) within the alveolar spaces,
allowing virus entry (Fig 1) (5). This correlates with
the observation that the earliest lung injury is often
seen in the distal airways (64). As discussed previously, alveolar damage is also attributable to the release of cytokines and chemokines that allow fluids
to fill the pulmonary interstitium and acini, and the
hypercoagulable state associated with COVID-19
that results in micro- and macrothrombosis of the
pulmonary vasculature (65).

Role of Imaging
Chest radiography is typically the first-line
imaging modality performed in patients with
suspected COVID-19 infection. At patient admission, initial posteroranterior or anteroposterior
(AP) chest radiographs are obtained, usually with
the use of an intervening glass door to minimize
exposure to the technologist (this technique
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Figure 2. COVID-19 progression over 4 days in a 28-yearold man. (a) Posteroranterior chest radiograph shows bilateral
multiple peripheral and lower lobe GGOs (arrows). (b) Axial
non–contrast material–enhanced CT image obtained 4 days
later shows progression of the typical appearance of COVID
pneumonia, manifesting with bilateral GGOs (arrowheads), peripheral on the right and diffuse on the left. In addition, there is
rapid worsening of the lung pneumonia, with development of
bilateral lower lobe airspace consolidations (arrows).

provides adequate quality for chest radiograph
acquisition when compared with that of conventional methods) (66). Pulmonary consolidations
and other pneumonia-related changes may be
diagnosed when interpreting images obtained
using this technique, as well as changes related to
ARDS in patients who are critically ill. At early
stages of disease and in mild cases, findings at
chest radiography may be normal. Wong et al
(64) found that initial chest radiography findings
were abnormal in 69% of patients who required
hospital admission, and in 80% of patients who
had already been hospitalized (64).
Chest Radiography and CT.—The most com-

monly reported findings of COVID-19 at chest
radiography include lung consolidation and
ground-glass opacities (GGOs)(67). Reticular
opacities may accompany areas of GGOs and can
be well depicted on standard chest radiographs.
Viral pneumonias, including COVID-19, typi-
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cally produce lung opacities in more than one
lobe. Additionally, evidence of multifocal airspace disease on chest radiographs can be indicative of COVID-19 pneumonia, most frequently
in a lower lung distribution and bilateral (Fig 2).
Peripheral lung involvement is one of the most
specific features of this infection, although it
may resemble other inflammatory processes with
multifocal, patchy, or confluent distribution of
findings, such as organizing pneumonia (Fig 3).
A pattern of diffuse lung opacities may also be
seen with COVID-19 infection, as well as a number of other infectious and/or inflammatory processes, such as ARDS. During the disease course,
lung opacities may rapidly evolve into a diffuse
coalescent or consolidative pattern within 1–3
weeks after symptom onset, often peaking around
6–12 days after initial clinical presentation (Fig
3) (68,69). Pleural effusions, lung cavitation, and
pneumothorax are rare findings in COVID-19
and, when depicted on chest radiographs, should
raise suspicion for other potential causes (70–72).
In young and middle-aged patients, the extent
of GGOs at chest radiography have been shown
to correlate with the need for hospitalization and
performing intubation. Toussie et al (73) reported
that patients with GGOs depicted in at least two
lung zones are more likely to require hospitalization and those with GGOs in three zones were
more likely undergo intubation (73). On the basis
of the pattern and distribution of the opacities
and the presence or absence of certain clinical
signs (such as obesity), the authors developed a
chest radiography severity scoring system that
could be used as a prognostic factor of outcomes
in young adult patients with COVID-19 (Fig 3).
Advancements in new technologies such as
artificial intelligence have allowed the utilization of automated assessment and tracking of
COVID-19 pulmonary disease severity on chest
radiographs. The results of this artificial intelligence–based longitudinal assessment could
potentially be used for the prediction of patient
prognosis (with respect to the likelihood of requiring intubation or death) (74).
Chest radiography and chest CT may be performed as adjuncts in cases of an initial negative
RT-PCR test with persistent high clinical suspicion
for disease. The American College of Radiology
advises against using CT as a first-line tool in the
diagnosis of COVID-19, recommending that it be
used sparingly and reserved for symptomatic hospitalized patients with specific clinical indications,
such as assessment of complications (75,76).
Chest radiography is a less sensitive modality
for the detection of COVID-19 lung disease when
compared with that CT, with a reported baseline
chest radiography sensitivity of 69% (64). The

1580 October Special Issue 2020

radiographics.rsna.org

Figure 3. Longitudinal assessment of COVID-19 pneumonia progression in a 56-year-old man who presented
to the emergency department with dyspnea and dry
cough. (a) AP chest radiograph obtained at hospital admission at the time of symptom onset shows bilateral
pulmonary opacities (arrows) at the periphery of the
right mid lung and at the left lung base. (b) AP chest
radiograph obtained on day 8 of hospitalization shows
progression of multifocal opacities bilaterally, which
now involve more than two lobes, and interval development of bibasilar consolidations. These findings correspond to a higher severity score and carry a worse
prognosis. In addition, there is mild pulmonary edema,
suggestive of fluid overload. Note that the patient had
undergone intubation. (c) AP chest radiograph obtained on day 14 of hospitalization shows progression
of the multifocal bilateral peripheral opacities.

true sensitivity and specificity of CT for detection
of COVID-19 remains relatively unknown. One
study showed that radiologists identified cases of
COVID-19 versus other viral pneumonias correctly 60%–83% of the time on the basis of typical
CT features (77). However, the results of this
study should be treated with caution, as the control and COVID-19–positive groups evaluated in
this study came from two different institutions (the
cases of COVID-19 came from China and control
cases from the United States) (78).
Pulmonary US.—Pulmonary US is another

imaging modality that has been shown to be
useful in the evaluation of critically ill patients
with COVID-19, as it can be performed at the
bedside and allows detection of pneumonia
(79). The most commonly depicted features of
lung involvement at US include the presence of
B-line artifacts, an irregular thickened pleura,
and subpleural consolidations (Fig 4, Movies 1,
2) (80). B-line artifact distribution corresponds
to subpleural thickened interlobular septa, as
demonstrated at CT. B-line artifacts are vertically oriented, highly dynamic, and hyperechoic
artifacts that originate from the pleura or from
areas of consolidation that usually manifest in pa-

tients with alveolar-interstitial syndrome (80–82).
These lines indicate accumulation of fluid in the
pulmonary interstitial space (lung rockets) or
alveoli (ground glass). When multiple, they are
associated with pulmonary edema of cardiogenic,
noncardiogenic, or mixed origin and are indicative of lung interstitial syndrome. B-line artifacts
usually move with lung sliding. Absence of lung
sliding should raise concern that the lung is not
inflated or that there may be a pneumothorax.
CT Pulmonary Angiography.—Contrast-enhanced CT pulmonary angiography is performed
to assess for possible PE in patients who develop
acute dyspnea or acute deterioration of respiratory symptoms, or those in whom d-dimer
markers are significantly elevated. The utilization
of pulmonary scintigraphy (ventilation–perfusion
scanning) in patients with suspected COVID-19
pneumonia should be limited, unless deemed
essential for medical management. If ventilation–perfusion scanning is deemed necessary, the
ventilatory phase of the examination should be
eliminated and only the perfusion phase should
be performed (83). Dual-energy CT has also been
shown to be helpful for the evaluation of lung
perfusion abnormalities (84).
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Figure 4. Interstitial edema and pleural thickening in a 40-year-old man with COVID-19 who presented
to the emergency department with hypoxia and dyspnea. (a) Gray-scale lung US image obtained in the
longitudinal plane over the left lower lobe shows multiple (more than three) vertical echogenic bands
(white arrows) extending from the pleural surface to the deeper portions of the lung, consistent with Bline artifacts, indicating subpleural interstitial edema. Note that the lung pleura is thickened and irregular
(black arrow). (b) Corresponding AP chest radiograph shows multifocal bilateral patchy peripheral opacities (black arrows), with an area of consolidation (white arrow) in the left lower lobe with air bronchograms, which is indicative of organizing pneumonia.

Table 3: Imaging Classification and CT Features of COVID-19 Pneumonia
Imaging
Classification

Rationale

CT Features

Typical
Commonly reported Peripheral bilateral GGOs with or without consolidation or visible interlobular lines (“crazy-paving” pattern)
appearance
imaging features
of greater specific- Multifocal GGOs or rounded morphology with or without consolidation
or visible interlobular lines (crazy-paving pattern)
ity for COVID-19
Reverse halo sign or other findings or organizing pneumonia (seen later in
pneumonia
the disease)
Absence of typical features AND the presence of the following features: mulIndeterminate Nonspecific imagtifocal, diffuse, perihilar, or unilateral GGO with or without consolidation
appearance
ing features of
lacking a specific distribution and that are nonrounded or nonperipheral
COVID-19 pneuFew small GGOs, with a nonrounded and nonperipheral distribution
monia
Atypical
Uncommonly or not Absence of typical or indeterminate features AND the presence of the following features: isolated lobar or segmental consolidation without GGOs;
appearance
reported features
discrete small nodules (centrilobular; “tree-in-bud” appearance); lung
of COVID-19
cavitation; smooth interlobular septal thickening with pleural effusion
pneumonia
Source.—Adapted and reprinted under a CCBY 4.0 license from reference 78.

Chest CT and Reporting.—The role of chest

CT in COVID-19 is constantly evolving, with
respect to clinical evaluation and treatment decisions. Whereas the 7th Chinese Novel Coronavirus
Pneumonia Diagnosis and Treatment Plan incorporates CT into the criteria that clinically define
COVID-19, the American College of Radiology
and the Society of Thoracic Radiology, among
others, advocate its use only in cases that require
problem solving (75,85,86). The suitability of
chest CT has also been assessed in various scenarios by the Fleischner Society, which deemed
CT a major tool for diagnosis in patients with

worsening symptoms or those in an environment
that is resource constrained, with respect to RTPCR testing availability (87).
The recent Radiological Society of North
American expert consensus statement on reporting proposed standardized nomenclature and an
imaging classification for COVID-19 pneumonia
that involves four categories: typical appearance,
indeterminate appearance, atypical appearance,
and negative for pneumonia (Table 3) (78).
In an attempt to pursue standardized reporting,
a COVID-19 Reporting and Data System (CORAD) based on a five-point scale of suspicion for
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Figure 5. Temporal pulmonary changes of COVID-19 pneumonia at CT in a 36-year-old woman. (a–c) Axial
contrast-enhanced CT images obtained at hospital admission show patchy bilateral GGOs and interlobular
septal thickening (black arrows), with lower lobe predominance and subpleural involvement. Note also some
immediate subpleural sparing of the GGOs (white arrows in b and c). (d–f) Follow-up corresponding axial
contrast-enhanced CT images show evolving consolidative changes with volume loss, architectural distortion
(ovals), and bronchiectasis (arrows in e and f).

pulmonary involvement of COVID-19 at chest CT,
was introduced (85). The CO-RAD score is based
on the features depicted on nonenhanced chest
CT images, with level of suspicion ranging from
very low (CO-RADS 1) to very high (CO-RADS
5). Two additional categories were also created to
account for a technically insufficient examination
(CO-RADS 0) and RT-PCR–proven SARS-CoV-2
infection at the time of examination (CO-RADS 6).

CT Findings.—Similar to those at chest radi-

ography, the most suspicious CT features for
COVID-19 infection in the lungs include multifocal bilateral peripheral GGOs, with or without
focal consolidations, in lung regions close to
pleural surfaces, including the fissures (Figs 2,
5). Although subpleural involvement has been
frequently documented, subpleural sparing may
also be present (Fig 6) (85). There are two types
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Figure 6. GGOs and subpleural sparing in a 68-yearold man with COVID-19 and difficulty breathing. Axial
contrast-enhanced CT image shows bilateral diffuse peripheral GGOs with subpleural sparing (arrows).

Figure 7. Halo sign in a 19-year-old man who presented with persistent fever and cough for 9 days and
with positive test results for COVID-19. Axial nonenhanced CT chest image shows multifocal bilateral areas
of mixed GGOs, with central nodular masslike opacities
surrounded by ground-glass attenuation (arrows), a
characteristic finding of a halo sign. Note that the opacities are located at the lung periphery.

of GGOs that have been described: pure type and
a mixed pattern, which is characterized by the
presence of both GGOs and areas of consolidation
(Fig 5). At CT, GGOs with or without consolidation are typically depicted in a peripheral, posterior, and diffuse or lower–lung zone distribution
(67,78). Pure-type GGOs, the most commonly
observed pattern, usually develop between days 0
and 4 after symptom onset, peaking at 6–13 days
(69,88–90). Therefore, a negative chest CT examination should not be used to exclude the possibility of COVID-19, particularly early in the disease
process (78).
Later in the disease course, the frequency of
consolidation increases (Fig 5). In fact, Wang
et al (89) noted that after symptom onset, the
predominant imaging abnormality becomes a
mixed pattern of GGOs, which typically peaks
during days 12–17 of the illness and has been
shown to be the second most prevalent pattern thereafter. As discussed previously, similar
temporal changes have been observed on plain
radiographs (Fig 3) (89).
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Pulmonary vascular abnormalities such as
vessel enlargement and regional mosaic perfusion patterns are also commonly found in
COVID-19 pneumonia (84). Other more atypical or infrequent signs described in patients with
COVID-19, such as the halo and reverse halo
(or atoll) sign, usually manifest later in the
disease course and are often absent at the time
of symptom onset (Figs 7, 8) (78). The halo
sign describes a nodule or mass surrounded by
ground glass opacification, while the reverse halo
(or atoll) sign is defined as a crescent or complete
ring of consolidation that surrounds a focal area
of GGO (Figs 7, 8) (91). Both appearances may
be embedded within an area of consolidation.
However, it is important to note that these findings are not specific, as they have been previously
described in early stages of opportunistic invasive fungal infections in immunocompromised
patients (eg, aspergillosis, mucormycosis), as
well as in immunocompetent patients diagnosed
with nonfungal endemic infections, cryptogenic
organizing pneumonia, vasculitis, neoplasm, and
inflammatory diseases (91).
Unifocal unilateral lesions are uncommon and found only in 2% of patients with
COVID-19 (Fig 9) (92). The development of
gelatinous mucus secretions may be responsible
for lung collapse that can coexist with adjacent
areas of consolidation. Contrast-enhanced CT
aids in the differentiation of collapsed atelectatic lung from pneumonia by demonstrating
parenchymal lung enhancement within atelectatic lung and absent or markedly diminished
lung enhancement in the setting of pneumonia
(Fig 10). Bronchial wall thickening was described in 10%–20% of patients with COVID-19 (Fig 11) (93). Pleural effusion, cavitation, pulmonary nodules, tree-in-bud opacities,
and lymphadenopathy have not been reported
in patients with COVID-19 and can be useful
in differentiating COVID-19 pneumonia from
other conditions (94).
In normal lung, subsegmental vessels are usually inconspicuous within the subpleural regions.
However, it has been shown that many patients
with COVID-19 exhibit tortuous and dilated
distal vessels in the subpleural lung (84). These
findings should not be confused with pulmonary
vascular thickening (or thick vessel sign) within
pulmonary opacities in COVID-19 pneumonia,
which has been reported to range from 59% to
82% in patients with COVID-19 (77,95,96).
Pulmonary vascular thickening is a nonspecific
sign and can be seen in other conditions, including pulmonary hypertension, pulmonary venoocclusive disease, hepatopulmonary syndrome,
and portopulmonary hypertension (97).

1584 October Special Issue 2020

radiographics.rsna.org

Figure 8. Reverse halo sign in a 76-year-old
man with COVID-19 and a history of pancreatic
cancer. (a, b) Axial (a) and coronal (b) contrastenhanced CT images show a nodular opacity
(black arrow) in the right lower lobe, with central GGOs and peripheral solid consolidation,
consistent with a reverse halo sign. Note the
subtle bilateral peripheral GGOs (white arrows).
(c) Axial contrast-enhanced CT image obtained
3 weeks after diagnosis shows subsequent resolution of the reverse halo sign, with vague residual
opacity (circle).

Acute Respiratory Disease Syndrome
One of the most common respiratory complications of COVID-19 infection is ARDS (Fig 12).
While ARDS is a clinical diagnosis that has a
grading system based on the degree of hypoxia,
imaging plays a supportive role in its diagnosis
and management. It has been suggested that
abnormal pulmonary vasoregulation may play a
large role in patients with COVID-19 infection
before the onset of radiologic or clinical manifestations that would suggest ARDS, and may be
even more pronounced when ARDS does occur
(84,98). The presence of disordered vasoregulation is supported by the frequency of pronounced dilatation of vasculature within regions
of diseased lung, leading to significant ventilation and perfusion mismatches early in the
disease. Perfusion abnormalities in the setting of
COVID-19 pneumonia, most optimally assessed
at dual-energy CT, may suggest an underlying
vascular process.
Chest radiography and CT can aid in the
identification of additional underlying causes of
ARDS symptoms, such as superimposed bacterial pneumonia or congestive heart failure,
although findings are frequently nonspecific.
In the acute phase of ARDS, chest radiography may demonstrate bilateral airspace opacities with air bronchograms (Fig 13). Unless
pulmonary edema is also present, septal lines
and pleural effusions are not expected findings.
In the acute exudative phase of ARDS, within
the first week, CT demonstrates diffuse GGOs

Figure 9. Focal unilateral opacity in a 52-year-old
woman who presented with persistent cough and
positive COVID-19 RT-PCR and immunoglobulin G
antibody test results. Axial nonenhanced chest CT
image shows a focal unilateral 3-cm rounded peripheral GGO (arrow).

in a posterior and basal predominance, and a
crazy-paving pattern may also be depicted (Fig
13). The crazy-paving appearance is thought
to be attributable to superimposition of thick
interlobular septa on GGOs and was detected
in 36% of patients with COVID-19 (69). In the
subsequent subacute phase of ARDS, consolidations may develop posteriorly or anteriorly if the
patient is prone, with reversible bronchiectasis
(Figs 11, 14). In the late phase of ARDS, more
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Figure 10. COVID-19 pneumonia complicated by mucus plugging and lung collapse in
a 78-year-old man who presented with shortness of breath and suspicion of PE. Axial (a)
and coronal (b, c) chest CT angiographic images show patchy GGOs (arrowheads in b) on
the right and left lung opacification with volume loss in the left upper lobe due to atelectasis. Adjacent atelectasis and pneumonia in the
left upper and lower lobes are evidenced by
enhancement of the atelectatic lung (black arrow in c) and absence of enhancement within
the pneumonic consolidation (white arrow
in c). Atelectasis was caused by the presence
of thick mucus that resulted in bronchial obstruction and subsequent collapse.

Figure 11. Bronchial dilatation in an
83-year-old man with COVID-19 with persistent hypoxia and a sudden increase in d-dimer
levels, findings concerning for PE. Coronal CT
angiographic image shows extensive bilateral bronchial dilatation with bronchial wall
thickening (black arrows) and bilateral diffuse
posterior lung GGOs, as well as interlobular
septal thickening (white arrows), greater on
the left than on the right, consistent with the
later stages of COVID-19 pneumonia.

than 2 weeks after onset, CT images can show
signs of fibrosis, with architectural distortion,
reticulation, and traction bronchiectasis (Figs 5,
13, 14) (99).
Patients admitted to the ICU with barotrauma as a result of intubation or as a complication of ARDS may develop pneumothoraces
or pneumomediastinum, further complicating
the pulmonary manifestations of COVID-19
infection (Figs 14–16). In fact, patients with

COVID-19 who require mechanical ventilation
were found to be at increased risk of barotrauma
when compared with patients with ARDS alone
and patients without COVID-19. Barotrauma
was associated with a longer length of hospital stay and was an independent risk factor for
death in patients with COVID-19 (100).

Pulmonary Embolism
PE is another complication of COVID-19 infection, described in further detail in the “Peripheral and Central Vascular Manifestations of COVID-19” section. In recently published studies,
the incidence of PE in patients with COVID-19
who underwent pulmonary CT angiography
was reported to be between 23% and 30%
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Figure 12. Schematic illustration of the effects of SARS-CoV-2 virus and virus-activated cytokine storm and their role in the development of ARDS and multiorgan failure (MOF). Note that a similar mechanism can be applied to any solid or hollow organ in the
body that expresses ACE2 receptors on its surface. IFN-γ = interferon γ, IL-1 = interleukin-1, IL- 6 = interleukin-6, IL-8 = interleukin-8,
TNF-α = tumor necrosis factor-α.

Figure 13. COVID-19 pneumonia with superimposed ARDS in a 61-year-old man who presented to the emergency department with hypoxia and subsequently underwent intubation. (a) AP chest radiograph shows bilateral diffuse lower-lobe predominant opacities (arrows), compatible with COVID pneumonia. (b) Coronal
nonenhanced chest CT image shows “crazy-paving” pattern, with diffuse bilateral GGOs, interlobular septal
thickening, and intralobular lines, a typical appearance of COVID-19 pneumonia.

(50,101,102). Currently, there are conflicting
results as to whether there is increased probability of PE in patients with COVID-19 who are
receiving intensive care or require mechanical
ventilation when compared with those who are
not admitted to the ICU (50,102).
A notable risk factor for the development
of PE is obesity, with recent data showing that
patients with a body mass index greater than 30
kg/m2 are 2.7 times more likely to develop PE.
Additionally, African American patients are at
higher risk of developing PE when compared

with other ethnic groups (102). With respect
to the location and distribution of thrombi, PE
is more commonly found in the segmental and
lobar branches and less commonly in the central
pulmonary arteries (Fig 17) (102).
Long-term effects of the disease and followup long-term imaging sequelae have not been
well established at this point and are still under
investigation. Organ-specific vascular manifestations and complications will be discussed in the
corresponding part 2 article in a future issue of
RadioGraphics.
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Figure 14. Time course of lung changes in a 59-year-old man with COVID-19 pneumonia evaluated at
chest radiography and CT over a 2-month period, which was complicated by development of a pneumothorax. (a–c) AP chest radiographs obtained at hospital admission (a), 4 days later (b), and 1 month later (c)
show a peripheral patchy opacity in the left mid lung (oval in a) at the initial assessment, with substantial
progression of lung disease on day 4 (b), with development of multiple bilateral peripheral areas of consolidation. The radiograph obtained 1 month later (c) shows interval improvement of the bilateral areas of
consolidation and an increase in reticular opacities (dashed arrows in c), with the development of bronchial
dilatation (solid arrow in c). Note that at this time the patient had undergone tracheostomy. (d, e) Axial (d)
and coronal (e) contrast-enhanced chest CT images, obtained at the same time as c for worsening shortness of breath, show diffuse GGOs associated with superimposed interlobular reticulations, resulting in a
crazy-paving pattern (dashed black arrows) and bronchial dilatation (black solid arrows in e). The findings
were complicated by the presence of a moderate-sized anterior pneumothorax (white arrows), which was
not well appreciated on the plain radiograph (c).
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Peripheral and Central Vascular
Manifestations of COVID-19
Pathophysiology of Vascular Thrombosis
There is growing evidence of coagulopathy related
to COVID-19, which may predispose patients to
both venous and arterial thromboembolism and
result in deep venous thrombosis (DVT), PE,
limb ischemia, stroke, and myocardial infarction
(103–105). Although the pathogenesis and incidence of thrombotic complications are not clearly
understood, coagulopathy has been noted to be a
poor prognostic indicator and is associated with
higher mortality (60,103,106,107).
The most common pattern of coagulopathy
observed in patients hospitalized with COVID-19
is characterized by elevated d-dimer and fibrinogen levels (108) and correlates with a parallel
rise in inflammatory marker levels, including but
not limited to levels of C-reactive protein, tumor
necrosis factor-α, and various interleukins (Fig
18) (54,107–109).
Initial data have demonstrated that COVID-19–associated coagulopathy manifests with
features of both sepsis-induced coagulopathy
and thrombotic microangiopathy (54,107–109).
Multiple factors, including inflammatory cytokine
release, critical illness, platelet activation, and
endothelial dysfunction, play a role. This is further
evidenced by recent histologic data that have demonstrated diffuse alveolar damage, microthrombi
formation, and occlusion of small pulmonary
vessels (65). However, it is still uncertain whether
COVID-19 has other unique characteristics that
result in direct activation of coagulation.
As seen in other infections that result in
sepsis-induced coagulopathy, the primary
infection of COVID-19 initiates cellular injury and results in an inflammatory response,
which includes production of inflammatory
cytokines, endothelial activation, and recruitment of neutrophils and mononuclear cells.
The activation of coagulation is a host immune
response that contributes to the compartmentalization of pathogens in an attempt to prevent
dissemination. However, endothelial cell dysfunction results in excess thrombin production
and disrupted fibrinolysis, which results in a
hypercoagulable state. Following cellular injury,
tissue factor, which is a critical initiator of the
extrinsic coagulation pathway, is expressed on
macrophages, monocytes, and endothelial cells
and plays a central role in the development of
coagulopathy and disseminated intravascular coagulation. Additionally, fibrinolysis is suppressed
in sepsis (110,111).
Compared with the typical pattern of sepsisinduced coagulopathy, patients with COVID-19

Figure 15. COVID-19 complicated by pneumothorax
and pneumomediastinum in a 59-year-old man who
underwent intubation with increased oxygen requirements. Posteroranterior chest radiograph obtained in
the prone position shows moderate-size right pneumothorax and small left apical pneumothorax (black
arrows). Pneumomediastinum is evident by the presence of air around the aortic arch and beneath the heart
(red arrows). The endotracheal tube and feeding tube
are in place. A large amount of subcutaneous emphysema is depicted bilaterally (white arrows). The patchy
bilateral hazy opacities are compatible with COVID-19
pneumonia.

Figure 16. COVID-19 complicated by pneumomediastinum in a 61-year-old man. Axial (a) and coronal (b)
chest CT angiographic images show a typical appearance of COVID-19 pneumonia, including diffuse GGOs
and interlobular septal thickening (black arrows). Air is
depicted anterior to the pulmonary artery (white arrow
in a) and adjacent to the main pulmonary artery and
left atrial appendage (white arrow in b), indicative of
pneumomediastinum.
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Figure 17. Saddle embolus in a 52-year-old man who presented to the emergency department with hypoxia and tachycardia and
received positive test results for COVID-19. (a–c) Axial chest CT angiographic images show a saddle embolus (arrows in a), extending into the lobar and segmental pulmonary artery branches bilaterally, and associated dilatation of the right ventricle, suggestive of
right heart strain (arrow in b). Patchy peripheral GGOs on the right and a nodular area of consolidation (arrows in c) on the left are
typical findings of COVID-19 pneumonia. (d) Gray-scale (left) and corresponding color Doppler (right) US images of the left femoral
vein (FV) obtained in the transverse plane show a partially occlusive thrombus (arrows). The vein was not compressible at manual
compression (not shown).

are diagnosed with less prominent thrombocytopenia (111). Additionally, prothrombin time
and partial thromboplastin time remain near
normal and fibrinogen levels are elevated until
later in the disease process when they decrease
and patients subsequently develop disseminated
intravascular coagulation (57,107–109).
Additionally, authors of a recent study have
suggested that a small subset of severe COVID-19 cases demonstrate complement-mediated microvascular injury and thrombosis, consistent with activation of the alternative pathway
and lectin pathway cascades (112).
It is also important to note that hypoxia itself
can stimulate thrombosis through an increase in
blood viscosity and a hypoxia-inducible transcription factor–dependent signaling pathway.
Additionally, ARDS may be a potential cause for
hypoxic pulmonary vasoconstriction, pulmonary
hypertension, and right ventricular failure (104).
Aside from hemostatic derangements, underlying comorbidities (cancer, obesity, etc) and
immobility and the use of mechanical ventilation,

central venous catheters, and extracorporeal circuits contribute to thrombotic risk. In addition,
current investigational medications for treating
COVID-19 may have adverse drug-drug interactions with antiplatelet agents and anticoagulation
therapy (113).
To summarize, the pathophysiology of the
hypercoagulable state found in association with
COVID-19 disease is extremely complex and
multifactorial in nature, with many varied factors
playing a role in its occurrence (Fig 18).
It is important to note that the existing
evidence is primarily derived from a few small
retrospective analyses, and further evaluation
with large prospective cohort studies must be
conducted to better understand this illness.

Role of Imaging
Duplex US, MR angiography, and CT angiography, as well as MR and indirect or combined
CT venography are the primary noninvasive modalities for the diagnosis of arterial and venous
thrombosis and thromboembolism in patients
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Figure 18. Diagram shows the multifactorial mechanisms of coagulopathy related to COVID-19. CRP = C-reactive protein, IFN-γ =
interferon γ, IL-1 = interleukin-1, IL- 6 = interleukin-6, IL-8 = interleukin-8, PAI-1 = pasminogen activator inhibitor-1, PT = prothrombin
time, PTT = partial thromboplastin time, TNF-α = tumor necrosis factor-α.

with COVID-19 (114,115). However, it is important to note that these disease processes may
also be detected at routine contrast-enhanced
CT performed in the portal venous phase, particularly when the main or large branch vessels
are affected. Taking into consideration that many
multiorgan and multisystem complications of
COVID-19 are caused by or directly associated
with vascular thrombotic events, careful assessment of the vasculature is essential in the evaluation of all imaging examinations performed in
patients with COVID-19.

Venous Thromboembolism
The risk of venous thromboembolism (VTE),
which is already greater in all critically ill
patients, is higher in those with critical illness due to SARS-CoV-2 infection (116). An
ever-increasing number of published studies
have assessed the risk of VTE in patients with
COVID-19, with reported incidences of DVT
ranging from 25% to 49% (54,116–118). The
incidence was found to be much higher if both
symptomatic and asymptomatic patients were
assessed and in patients with prolonged hospital
stays in the ICU (cumulative incidence rates
were as high as 59% at 21 days of hospitalization) (118). The wide range of reported incidences can be explained by the fact that VTE
remains largely underdiagnosed in patients with
severe COVID-19, as only symptomatic patients

generally undergo imaging. This is in part due to
the contagious nature of COVID-19, as its high
transmissibility rate complicates the workup of
patients with infection. In an attempt to minimize exposure to radiologic technologists and
transport personnel, only symptomatic patients
are typically eligible to undergo imaging, often
using abbreviated protocols and portable machines that may result in a limited evaluation.
Additionally, the concern over shortages of
personal protective equipment (PPE) influenced
the number and types of examinations that were
offered to this group of patients. Underdiagnosis
of complications of VTE in patients with COVID-19 is a significant issue, as many of these patients who are severely ill already have ARDS and
its complications (including hypoxic pulmonary
vasoconstriction, pulmonary hypertension, and
right ventricular failure), and further insult from
a PE may be fatal. It is important to note that
veins of any caliber may be affected, and therefore all vessels should be scrutinized for potential
thrombus.
Elevated d-dimer levels, commonly found in
patients with COVID-19, do not currently warrant routine investigation for acute VTE in the
absence of clinical manifestations or other supporting information (119). However, in patients
with high clinical suspicion for VTE, there should
be a low threshold for ordering diagnostic tests to
evaluate for DVT and/or PE.
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Figures 19–21. (19) Occlusive DVT of the femoral vein in an 88-year-old man who had been hospitalized with COVID-19. Gray-scale (left) and color Doppler (right) US images obtained in the transverse plane
show dilated femoral veins (white arrows), with internal heterogeneous echogenic material and absence of
flow on the color Doppler US image, findings compatible with occlusion. The veins were noncompressible
(not shown). Note that the femoral artery is filled with color, indicative of patency (black arrows). (20) DVT
associated with a peripherally inserted central catheter (PICC) line in a 54-year-old man with COVID-19.
Sagittal color Doppler US image shows an echogenic thrombus (black arrows) in the right subclavian vein,
associated with the PICC line (white arrow). (21) Partially occlusive thrombus in the left popliteal vein (L
POP V) in a critically ill 64-year-old man with COVID-19 who acutely developed left leg swelling. Laboratory
test results confirmed elevated d-dimer levels. Gray-scale (left) and power Doppler (right) US images show
a dilated left popliteal vein with echogenic thrombus (arrows) within, best visualized on the gray-scale US
image. Power Doppler image US (right) shows absence of flow within the distended vein except for a small
amount of flow within the lumen of the vessel, indicative of a partially occlusive thrombus.

The imaging examinations performed to diagnose DVT or PE in patients with COVID-19 may
not be requested or performed, potentially owing
to patient instability. Moreover, performing imaging examinations may be challenging in patients
with severe ARDS who require prone positioning.
Investigating for PE as well as lower and upper
extremity DVT may not always be feasible owing
to these clinical and positioning issues. Although
deterioration of right ventricular function in this
setting may be a critical finding that justifies the
need for establishing a diagnosis of PE, it could
also be argued that the prognosis of patients with
ARDS who require prone positioning is so grave
that investigation for an underlying VTE may not
alter the clinical course. Preventive and therapeutic use of antithrombotic agents is helpful toward
mitigating the occurrence thrombotic and hemorrhagic events in these high-risk patients (104).

Lower and upper extremity Doppler US is
the first-line imaging modality for diagnosis of
peripheral venous thrombosis and can be performed at the bedside. Occlusive and partially
occlusive thrombi and their potential associations
with central lines can be readily diagnosed (Figs
19–21). Noncompressible veins, echogenic clot,
and minimal or absent flow within a distended
vein are the US hallmarks of acute or subacute
DVT (Figs 21–23). Superinfection may result in
thrombophlebitis and can be diagnosed by the
demonstration of hyperemia in the wall of an
otherwise thrombotic vessel at color Doppler US.
In cases of incomplete and/or inadequate thrombus evaluation or extension of thrombus into a
more central vessel, CT and MR venography can
be employed (Fig 24). The presence of a filling
defect within a vessel, with or without occlusion,
is the characteristic finding of venous thrombosis.
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Figures 22,23. (22) Superficial vein thrombosis in a 72-year-old woman hospitalized with
COVID-19. Transverse gray-scale (left) and color Doppler (middle) US images without compression and gray-scale US image with compression (right) show an occlusive thrombus in
the dilated basilic vein (black arrows). Note the absence of flow within the vein on the color
Doppler US image (middle) and noncompressibility of the vein (left). The brachial veins (white
arrows) are compressible (right) and demonstrate patency on the color Doppler US image
(middle). (23) Extensive bilateral upper extremity DVT in a critically ill 77-year-old man with
COVID-19 who developed bilateral upper extremity swelling, with markedly elevated d-dimer
levels (31 447 ng/mL). (a, b) Sagittal color (a) and power (b) Doppler US images show absent
flow in the distended vein, with echogenic material in the left subclavian vein (arrow in a) and
the right axillary vein (arrows in b), compatible with bilateral occlusive thrombi. Additional
occlusive and nonocclusive thrombi were also seen (not shown). (c) Gray-scale US images
without (left) and with (right) compression show a thrombus (arrows) in the right cephalic
vein, which demonstrates no vascular compression (arrows).

Arterial Thrombosis
The authors of only a few studies to date have
evaluated the frequency of peripheral arterial
thrombosis in patients with COVID, with a
reported incidence of 3.7% (116). The authors
of a few reported cases of lower extremity arterial thrombosis have suggested a link between
preexisting peripheral arterial disease and the
development of arterial thromboembolism. It
has been hypothesized that acute and progressive thrombosis may be attributable to a combination of the hyperinflammatory state induced
by COVID-19 superimposed on a preexisting
condition (120,121).
Doppler US and CT angiography of the
extremity vessels are both instrumental in the
evaluation of peripheral arterial thrombosis. At

US, absence of flow within an arterial segment
is diagnostic of an occlusive thrombus. Abnormal waveforms (stump waveforms), character-
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Figure 24. Inferior vena cava (IVC) and peripheral deep vein thrombosis in a 78-year-old
man with COVID-19 with leg swelling and abdominal pain. Sagittal (a) and axial (b) contrastenhanced CT images show filling defects in the bilateral common femoral veins (solid arrows).
Near complete occlusion of the IVC (solid arrows in a) to the level of an IVC filter (dashed arrow in a) was present. Note the renal transplant (arrowhead in a). Both central and peripheral
venous thrombosis were not depicted at prior imaging examinations (not shown).

ized by a low amplitude and high-resistance
pattern with absence of diastolic flow, can aid in
identification of a more distal occlusion. Alternatively, tardus parvus waveforms within more
distally recanalized vessels are findings suggestive of a more proximal significant stenosis or
occlusion (Fig 25). Reconstituted flow, sometimes with collateralization, may be depicted
distal to an occlusion. Peripheral and central
arterial thromboembolism may also be the result
of atrial fibrillation.
CT angiography aids in the assessment of the
extent of thrombosis and its potential complications such as ischemia to a related structure or
organ. An abrupt cutoff of the affected vessel
may be readily detected at CT angiography
(Figs 25–28, Movie 3). The few reported cases
(122) of peripheral arterial thromboembolism
associated with COVID-19 have involved both
upper and lower extremity arteries, and carotid
and vertebral artery involvement have been described as well. The larger central arterial system
may also be involved (eg, floating thrombi may
be visualized in the aorta and aortic arch) (Fig
29) (122). It is important to keep in mind that
COVID-19 can affect more than one organ or

structure, and every organ and vessel should be
scrutinized when assessing for complications
(Figs 27–29).
It is also essential to recognize that patients
with COVID-19 may develop thrombosis of
various vascular systems, and there could be
concomitant involvement of one or more venous
or arterial vascular beds. Therefore, if evidence of
thrombosis is detected, careful assessment of the
entire imaged vascular system, as well as correlated organ or structure, is essential.

Conclusion

SARS-CoV-2 is a novel coronavirus that has
rapidly resulted in a worldwide pandemic and has
been the cause of extreme morbidity and mortality. It primarily affects the respiratory system but
may also impact a multitude of other systems in
the human body, resulting in multiorgan injury and, in some cases, failure. Imaging plays a
significant role in the detection, diagnosis, and
assessment of virus-induced injury, as well as
its associated complications. A recognition and
understanding of the pathophysiology of the virus
and its effects on the immune system and coagulation is paramount toward improving radiologists’
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Figure 25. Popliteal and posterior tibial artery thrombosis in a 58-year-old woman
with COVID-19 in the ICU. (a, b) Sagittal color (a) and spectral (b) Doppler US images show an echogenic heterogeneous thrombus (white arrows) distending the right
popliteal artery. The characteristic knocking or “stump-thump” waveform with absence
of diastolic flow (black arrows in b) and low amplitude (yellow circle in b) imply the
presence of occlusion just distal to the area of interrogation. (c) Sagittal power Doppler
US image shows no flow in the occluded right posterior tibial artery (black arrows).
(d) Corresponding sagittal CT angiographic reconstruction shows abrupt cutoff of the
popliteal artery by a thrombus (solid arrow). Note the opacified popliteal artery (Rt POP
A) proximal to the thrombus (dashed arrow). The patient also had a liver infarct and
bowel ischemia (not shown).

Figure 26. Popliteal artery occlusion in a severely ill
65-year-old man with COVID-19 with bilateral diminished dorsalis pedis pulses. Coronal three-dimensional
volume-rendered run-off CT angiographic image
shows abrupt cutoff (arrows) of the bilateral popliteal arteries (PA), compatible with bilateral occlusion.
Note that distally run-off calf arteries have been reconstituted through collateral arteries. R LE = right lower
extremity, L LE = left lower extremity.

ability to accurately identify key imaging findings
and promptly recognize possible complications,
specifically those affecting the pulmonary and
vascular systems, thereby minimizing the number
of diagnostic misses and misinterpretations.
Appropriate application of the described
chest radiography and CT scoring systems in the
evaluation of lung involvement, including automated assessment, may increase the consistency
of reported findings and aid in risk stratification,
as well as offer prognostic information. Owing
to the complexity of the viral pathophysiology
and its targeting of multiple organ systems, the
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Figure 27. Brachial artery
thrombosis and renal infarct
in a 51-year-old man who presented to the emergency department with acute left upper
extremity pain and numbness.
The patient had a 2-week history of cough and fever and
was confirmed to be COVID-19
positive. (a) Coronal left upper
extremity CT angiographic image shows an abrupt segmental
occlusion (arrow) of the distal
left brachial artery, indicative of
peripheral arterial thromboembolization. The left subclavian
and axillary arteries were otherwise unremarkable, with good
opacification of the arteries.
(b) Coronal three-dimensional
maximum intensity projection shows abrupt cutoff (arrow) of the left brachial artery.
(c, d) Axial chest CT angiographic images show the typical appearance of lung changes
in COVID-19 pneumonia (arrows in c). Note the incidentally
found sharp well-defined area
of nonenhancement in the partially imaged upper pole of the
right kidney, a finding indicative
of a renal infarct (arrows in d).

Figure 28. Common carotid artery (CCA) occlusion in a 56-year-old woman with neurologic
deficits who had been hospitalized with COVID-19.
(a, b) Coronal three-dimensional maximum intensity projection reformatted image (a) and axial CT
angiographic image (b) of the head and neck show
an abrupt cutoff at the origin of the CCA (black arrow in a). Note the absence of opacification of the
right CCA, as well as internal and external carotid
arteries (arrows in b). The left carotid vasculature
is well opacified with intravenous contrast material
(white arrow in a). (c) Axial nonenhanced head CT
image shows wedge-shaped areas of hypoattenuation (arrows) in a watershed distribution, consistent
with acute infarcts related to carotid occlusion.
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Figure 29. Central and peripheral arterial thrombosis in a severely ill 46-year-old man with COVID-19 in the ICU. (a, b) Axial (a)
and sagittal (b) chest CT angiographic images show bibasilar areas of consolidation (black arrows in a), indicative of COVID-19
pneumonia, and a central aortic thrombosis with a thrombus attached to the wall of the aortic arch (white arrow in a and b).
(c–f) Sagittal (c), coronal (d), and axial (e, f) CT angiographic images show a large thrombus extending from the abdominal aorta
into the superior mesenteric artery origin (arrow in c), which resulted in bowel ischemia, evidenced by thickening of the watershed
splenic flexure of the large bowel (arrow in d). Note the multifocal bilateral wedge-shaped renal cortical infarcts (arrows in e). Note
also a nonocclusive thrombus in the left profunda femoris artery (white arrow in f), indicative of a concurrent presence of a peripheral thrombosis. There is normal opacification of the patent right profunda femoris artery (black arrow in f). This case demonstrates
multifocal multisystem manifestations of COVID-19 complicated by coagulopathy that resulted in injury to various organs and
systems. It is an example of the need for increased awareness among radiologists to thoroughly evaluate all covered anatomy for
COVID-related complications.

recognition of one complication should prompt
intense scrutiny for others, particularly if the
patient is critically ill. A thorough knowledge of
diagnostic imaging hallmarks, atypical imaging
features, multisystem manifestations, and evolution of imaging findings is essential to optimize
patient care.
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